CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 280 enrolled
Drug / intervention
GORE VIABAHN VBX Balloon Expandable Endoprosthesisdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03720704
NCT03720704N/AActive

Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels

W.L.Gore & Associates·observational·Posted Oct 25, 2018·Updated Apr 14, 2026

In Brief

An observational study evaluating GORE VIABAHN VBX Balloon Expandable Endoprosthesis for Peripheral Vascular Diseases. Active but no longer recruiting, targeting 280 participants across 11 sites in 5 countries.

Detailed Summary

The primary objective of the VBX 17-04 registry is to collect post-market safety and performance data of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) in peripheral vessels in patients who require interventional treatment

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Germany, Italy, Netherlands, Spain
Collaborators--

Timeline

N/AActive
201920202021202220232024202520262027
First PostedOct 25, 2018
Enrollment StartDec 18, 2018
Primary CompletionApr 13, 2022
Study CompletionJul 1, 2027
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 7.7 years ago

Interventions

GORE VIABAHN VBX Balloon Expandable Endoprosthesisdevice

GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted in peripheral vessels in patients who require interventional treatment.